Efficacy of Intravenous Gamma Globulin on Guillain-Barre Syndrome

Last updated: January 18, 2022
Sponsor: Ning Wang, MD., PhD.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Peripheral Neuropathy

Neurologic Disorders

Neuropathy

Treatment

N/A

Clinical Study ID

NCT04303962
MRCTA，ECFAH of FMU[2019]217
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Guillain-barre syndrome (GBS) is an acute immune-mediated polyneuropathy. Intravenous Gamma globulin is an effective therapy.Although high doses of gamma globulin are clinically effective, the patient's recovery and clinical prognosis vary. The establishment of a cohort study on the therapeutic effect of gamma globulin in Guillain-barre Syndrome is beneficial to the diagnosis of the disease and to the understanding of the natural course of the disease and the efficacy of drug treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Meet the Brighton Guillain-Barre Syndrome diagnosis criteria in 2014;
  2. Age ≥18;
  3. Patients with AIDP, AMAN and AMSAN;
  4. IVIG was treated within 2 weeks of onset; 6. GBS disability scale>2; 6. Cooperate withpatients who were followed up for 180 days and sign the informed consent;

Exclusion

Exclusion criteria:

  1. Age <18;
  2. Pregnant or nursing women;
  3. Patients with Chronic inflammatory demyelinating multiple peripheral neuropathy;
  4. Combined with other types of immune system diseases;
  5. Accept drugs that affect the function of the immune system within 5 or 3 months;
  6. Concomitant neoplastic diseases.
  7. The patient or guardian refused to sign the informed consent.

Study Design

Total Participants: 200
Study Start date:
April 27, 2020
Estimated Completion Date:
January 21, 2025

Connect with a study center

  • Department of Neurology,First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian 350005
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.